Anti-hepatitis C agents

RG7795 (ANA773 previously) is an experimental oral prodrug of isatoribine developed by Anadys Pharmaceuticals which forms an active metabolite that is an agonist for TLR7.

Ledipasvir/sofosbuvir (trade name Harvoni) is a two-drug combination for the treatment of hepatitis C.

Ribavirin is an anti-viral drug used for severe RSV infection; hepatitis C infection, including if persistent, and often in combination with peginterferon alfa-2b or peginterferon alfa-2a; as well as some other viral infections.

Filibuvir (also known as PF-00868554, PF-868554) was a non-nucleoside orally available NS5B inhibitor developed by Pfizer for the treatment of hepatitis C.

Sofosbuvir (brand name Sovaldi) is a nucleotide analog used in combination with other drugs for the treatment of hepatitis C virus (HCV) infection.

Miravirsen (INN; codenamed SPC3649) is an experimental drug for the treatment of hepatitis C, being developed by Santaris Pharma.

Dasabuvir (trade name Exviera in Europe) is an antiviral drug for the treatment of hepatitis C virus (HCV) infection.

Elbasvir (MK-8742) is a drug approved (FDA Jan 2016) for the treatment of hepatitis C.

Elbasvir/grazoprevir (trade name Zepatier ZEP-ah-teer) is a fixed-dose two drug combination for the treatment of hepatitis C, containing 50 mg elbasvir (a hepatitis C virus NS5A inhibitor) and 100 mg grazoprevir (an NS3/4A protease inhibitor).

Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection.

A combination product of three antiviral drugs ombitasvir, paritaprevir and ritonavir is used with the drug dasabuvir in the treatment of hepatitis C Virus Genotype 1a or 1b (HCV GT1a or GT1b).

Velpatasvir is an inhibitor of NS5A used together with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes.

Velpatasvir/sofosbuvir (trade name Epclusa) is a two-drug combination for the treatment of hepatitis C.

Setrobuvir (INN, USAN, also known as ANA-598) was an experimental drug candidate for the treatment of hepatitis C.

Beclabuvir (BMS-791325) is an antiviral drug for the treatment of hepatitis C virus (HCV) infection currently in clinical trials.

Ravidasvir (PPI-668) is an investigational NS5A inhibitor in clinical trials for chronic hepatitis C genotype 4.

Daclatasvir/sofosbuvir (trade name Darvoni) is a two-drug combination for the treatment of hepatitis C.